Dan Nandan is the CEO of Staffingly, Inc. With 25+ years in IT consulting and a decade leading healthcare BPO operations across India, Latin America, and Pakistan, his team now serves 800+ U.S. healthcare providers across medical, dental, pharmacy, and post-acute care verticals.
2026 Compliance Verified: HIPAA, SOC 2 Type II, ISO 27001, HITRUST-aligned workflows.
Featured in Computerworld →
State of Illinois. Registered Professional Nurse
Bincy Shiiju Kuriakose is a U.S.-licensed Registered Nurse (MSN, RN), NCLEX-RN certified, with expertise in hospital nursing, telehealth, and nursing education. She reviews every publication for medical accuracy, YMYL compliance, and evidence-based clinical context.
What Is Repatha prior authorization?
Repatha (evolocumab) is a PCSK9 inhibitor manufactured by Amgen. It blocks the PCSK9 protein, allowing LDL receptors on liver cells to clear more LDL cholesterol from the bloodstream. Patients self-inject once monthly (140mg) or every two weeks (140mg), depending on the prescribed regimen.
Repatha PA Criteria by Payer Type
While every insurer publishes its own PCSK9 inhibitor coverage policy, criteria follow a consistent framework. Understanding common requirements prevents documentation gaps that cause most denials.
Clinical documentation required by most payers
- Confirmed diagnosis: documented ASCVD, HeFH, HoFH, or elevated LDL-C with increased MACE risk (per 2025 expanded label)
- Maximally tolerated statin trial: most payers require 8-12 weeks on the highest tolerated statin dose. Document the specific statin, dose, duration, and reason for dose limitation (myalgia, CK elevation, hepatotoxicity, rhabdomyolysis risk)
- Ezetimibe trial: nearly all payers require ezetimibe (10mg) for 4-8 weeks in combination with maximally tolerated statin before approving a PCSK9 inhibitor
- LDL-C still above threshold: most commercial payers require LDL-C above 70 mg/dL (ASCVD) or above 100 mg/dL (HeFH without ASCVD) on maximally tolerated statin + ezetimibe
- Lipid panel within 30-90 days: a current fasting lipid panel showing LDL-C above the payer’s threshold is required with submission
- Prescriber qualification: cardiologist, lipidologist, or endocrinologist; some payers accept primary care with documented specialist consultation
Payer-specific examples:
- Cigna MA: documented ASCVD or FH, maximally tolerated statin + ezetimibe failure, LDL-C above threshold, cardiologist/lipidologist/endocrinologist prescriber, reauthorization every 12 months
- UHC: ASCVD/HeFH/HoFH diagnosis, maximally tolerated statin for 8+ weeks, ezetimibe for 8+ weeks, LDL-C above specified thresholds, peer-to-peer review available for denials
Reauthorization: Most payers require reauthorization every 6-12 months with updated lipid panels and documentation of adherence. Set calendar reminders 30 days before expiration.
Step-by-Step Repatha PA Process
JAMA Cardiology research shows PCSK9 inhibitors require 3-11 times more documentation items than other cardiometabolic drugs. Front-loading every required document saves weeks.
Step 1: Verify eligibility and formulary status. Log into the payer portal or call the pharmacy benefits line. Confirm drug coverage is active, check whether Repatha is on formulary (preferred vs. non-preferred vs. excluded), and identify step therapy requirements. If Praluent or Leqvio is the preferred PCSK9 inhibitor, determine whether a medical exception is needed.
Step 2: Gather all clinical documentation. Before submitting, collect: diagnosis with ICD-10 code (I25.10 for ASCVD, E78.01 for HeFH, E78.00 for HoFH), current fasting lipid panel (within 30-90 days), statin trial history with dates/doses/outcomes, ezetimibe trial history, letter of medical necessity from the prescribing cardiologist, relevant cardiac history (prior MI, stent, CABG, stroke), and prescriber NPI.
Step 3: Submit the PA request. Use the payer’s electronic portal or CoverMyMeds. Attach all clinical documentation with the initial request. Do not submit a partial request and plan to send records later. Incomplete submissions are the top cause of PCSK9 inhibitor denials.
Step 4: Track the request. Under CMS-0057-F (effective January 2026), payers must respond within 7 calendar days for standard requests and 72 hours for urgent requests. Monitor the portal daily. If the payer requests additional information, respond within 24 hours.
Step 5: Document the outcome. Record the approval number, authorized dates, approved quantity, and any conditions. Set a reauthorization reminder 30 days before expiration.
Parallel action: Enroll the patient in Amgen Assist 360 while the PA is processing. Qualifying patients can access Repatha at $0-$5/month copay during the review period, preventing treatment gaps.
Common Repatha Denial Reasons and How to Appeal
Pharmacy Times reported PCSK9 inhibitors had a 30.95% rejected prescription rate between 2015 and 2021, more than double the rate for other branded cardiometabolic drugs. Knowing the specific denial reasons builds stronger initial submissions.
Step therapy not completed. The payer says the patient has not tried maximally tolerated statin + ezetimibe. Document each statin trial separately with start date, end date, dose, side effects, and objective findings (CK levels, ALT/AST). Include ezetimibe trial dates and LDL-C response. If the patient has a contraindication to statins, provide the clinical basis through a step therapy override request.
LDL-C threshold not met. The submitted lipid panel shows LDL-C below the payer’s threshold. Confirm the payer’s exact LDL-C threshold before submitting (some payers use 70 mg/dL for ASCVD, others use 100 mg/dL). Submit the most recent lipid panel drawn while on maximally tolerated background therapy.
Incomplete documentation. The payer received the request but is missing required clinical records. Submit every document listed in the payer’s PCSK9 criteria checklist with the initial request. Do not assume the payer will reference records from prior authorization periods.
Non-qualifying diagnosis. The ICD-10 code does not match the payer’s covered indications. Ensure the code matches the payer’s criteria. Reference the 2025 expanded FDA label if submitting for elevated LDL-C with increased MACE risk.
The appeal process: Most payers allow 60-180 days to file an appeal. Submit a written appeal addressing the specific denial reason, include all original documentation plus additional evidence, and request a peer-to-peer review with the payer’s medical director. Include citations from the FOURIER trial and ACC/AHA guidelines. Over 80% of initial PA denials in Medicare Advantage are overturned on appeal (OIG/KFF data).
Save 40-70% with dedicated PA specialists
Book a 15-minute call. We will map your current prior authorization workflow, denial rates, and staff hours against what a dedicated team typically delivers in the first 30 days.
Repatha Medicaid Coverage: New York, New Jersey, and California
New York: NY Medicaid maintains a PDL administered through the Drug Utilization Review Board (DURB) requiring clinical PA for PCSK9 inhibitors. NY Medicaid MCOs (Fidelis, Healthfirst, Amerigroup NY, UHC Community Plan) each have separate formularies and PA portals. verify Repatha coverage with the patient’s specific MCO before submitting. NY’s Prescription Drug Formulary Transparency Act requires insurers to disclose formulary changes 60 days in advance, giving providers lead time to adjust PA strategies. Source: NY Medicaid Pharmacy
New Jersey: NJ FamilyCare maintains a PDL with PA requirements through DMAHS. NJ Medicaid MCOs (Horizon NJ Health, Aetna Better Health NJ, WellCare NJ, Amerigroup NJ, UHC Community Plan NJ) maintain separate formularies. NJ adopted CMS-0057-F timelines for Medicaid managed care, requiring 7-day standard PA turnaround starting January 2026. PA criteria and forms are published at njmmis.com. Source: NJ DMAHS Pharmacy
California: Medi-Cal maintains the Contract Drug List with PA requirements for PCSK9 inhibitors, processed by Medi-Cal Rx (Magellan) for FFS beneficiaries. CA managed care plans (LA Care, Health Net, CalOptima, Partnership HealthPlan) maintain their own formularies with separate PA criteria. California SB 282 requires health plans to disclose PA criteria for any formulary drug within one business day of provider request. Source: Medi-Cal Rx
Key takeaway: Submitting a Repatha PA to the wrong MCO portal or without checking the state’s preferred PCSK9 product creates avoidable delays. Verify MCO-specific formulary status before every submission.
The Repatha Biosimilar Timeline and What It Means for PA
As of early 2026, no biosimilar for Repatha (evolocumab) has been approved in the United States. Amgen’s primary U.S. patents for evolocumab expire in 2027. The Supreme Court’s 2023 ruling invalidated some of Amgen’s broader PCSK9 antibody patents, but more specific formulation and manufacturing patents remain. Biosimilar entry is most likely in late 2027 or 2028 depending on ongoing litigation.
When evolocumab biosimilars reach the market, payers will almost certainly add them as preferred products. Branded Repatha may shift to non-preferred or non-formulary status, with new step therapy requirements for the biosimilar before the branded product is approved. Patients stable on Repatha may face new PA requirements when their payer switches formulary preference.
Current competitive alternatives: – Praluent (alirocumab): another injectable PCSK9 inhibitor with similar PA requirements – Leqvio (inclisiran): a PCSK9-targeting siRNA with biannual dosing; some payers have begun adding inclisiran to PCSK9 step therapy requirements before approving Repatha
Track payer formulary announcements quarterly. Practices with documented PA workflows for evolocumab can adapt quickly by updating submission templates when formulary preferences shift.
Why Practices Outsource Cardiology Prior Authorization
PCSK9 inhibitor PA is not a standard drug authorization. It requires detailed clinical documentation, payer-specific criteria knowledge, step therapy exception workflows, and ongoing reauthorization tracking, which is why many practices route it to a dedicated cardiology prior authorization team.
JAMA Cardiology found that PCSK9 inhibitor PAs require 3-11 times more documentation items than other cardiometabolic drugs. A single Repatha PA submission takes 30-60 minutes when clinical records are gathered, the payer portal is accessed, and supporting documents are attached. If denied, the appeal and peer-to-peer review add another 2-4 hours. For a cardiology practice prescribing Repatha to 30+ patients, the workload consumes entire FTEs.
A full-time PA coordinator in the U.S. costs $48,000-$65,000 per year in salary alone. With benefits, training, and turnover, the true cost exceeds $80,000 per FTE.
Staffingly’s specialty PA specialists work at $399/week (volume discounts to $299/week) with no benefits overhead, no training gaps, and 48-72 hour onboarding. 70% cost savings compared to in-house hires.
What outsourced cardiology PA teams handle: – Repatha, Praluent, and Leqvio PAs across commercial, Medicare Part D, and Medicaid payers – Step therapy exception requests with clinical documentation – Denial follow-up, written appeals, and peer-to-peer review coordination – Reauthorization tracking with automated deadline alerts – Payer portal submissions across 50+ EHR systems – Amgen Assist 360 and manufacturer patient assistance program coordination
Staffingly by the numbers: – 99.2% clean claim rate – 800+ healthcare providers served – SOC 2 Type II, HITRUST, ISO 27001, and HIPAA compliant – 48-72 hour go-live
What Cardiology Practices Actually Say
Cardiology practice managers on Reddit’s r/cardiology and r/medicalbilling repeat the same themes: statin trial documentation rejected because doses and dates were not listed separately, FOURIER citations missing from medical necessity letters, and peer-to-peer reviews lost because the 5-day window closed before anyone flagged it. The recurring solution is a PCSK9-specific documentation template capturing every statin trial with drug name, start date, end date, max dose, and reason for discontinuation.
A 5-cardiologist practice in Manhattan, NY built a Repatha-specific template with ASCVD staging and FOURIER references, increasing first-pass approvals from 34% to 81% in 90 days. A 3-provider preventive cardiology group in Newark, NJ used NJ Medicaid’s supplemental rebate arrangement and a standardized step-therapy exception letter to overturn 22 Repatha denials through peer-to-peer review. A 7-provider cardiology group in Los Angeles, CA serving Medi-Cal managed care flagged every denial within 24 hours for P2P scheduling and converted 78% of initial denials into approvals.
What Did We Learn?
- Repatha (evolocumab) requires prior authorization from every major payer, and PCSK9 inhibitors carried a 30.95% prescription rejection rate between 2015 and 2021. Proactive, complete documentation is the only way to reduce this.
- Step therapy is the most common denial trigger. Document each statin and ezetimibe trial separately with dates, doses, and clinical outcomes before submitting.
- Submit everything in the initial request. Incomplete submissions are the top cause of delays. Enroll the patient in Amgen Assist 360 in parallel to prevent treatment gaps.
- State Medicaid rules differ. New York, New Jersey, and California each maintain their own preferred drug lists and MCO formularies, so verify the patient’s specific MCO before every Repatha submission.
